According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “
Several other equities research analysts have also recently issued reports on the company. Wedbush set a $31.00 price target on Aquestive Therapeutics and gave the company a buy rating in a research note on Friday, July 5th. HC Wainwright started coverage on Aquestive Therapeutics in a report on Monday, April 22nd. They issued a buy rating and a $10.00 price objective for the company. Finally, ValuEngine upgraded Aquestive Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $19.54.
Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.15). The business had revenue of $11.13 million for the quarter, compared to the consensus estimate of $10.46 million. Aquestive Therapeutics had a negative return on equity of 8,682.29% and a negative net margin of 119.15%. On average, equities analysts anticipate that Aquestive Therapeutics will post -2.96 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of AQST. Morgan Stanley lifted its position in shares of Aquestive Therapeutics by 706.1% during the 2nd quarter. Morgan Stanley now owns 17,323 shares of the company’s stock worth $73,000 after buying an additional 15,174 shares in the last quarter. Spark Investment Management LLC bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth approximately $80,000. JPMorgan Chase & Co. lifted its position in shares of Aquestive Therapeutics by 728.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 22,761 shares of the company’s stock worth $93,000 after buying an additional 20,014 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $105,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $108,000. 66.42% of the stock is currently owned by hedge funds and other institutional investors.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Featured Article: Bid-Ask Spread
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.